News & Media
Follow us on our path to driving innovation for immunocompromised people
Publications
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
Katharina Erb-Zohar, Susanne Bonsmann, Jörg Pausch, Melanie Sumner, Alexander Birkmann, Holger Zimmermann , Atef Halabi, Dirk Kropeit
Clin Pharmacol Drug Dev. 2024 Sep 25. doi: 10.1002/cpdd.1469
Pritelivir for The Treatment of Nucleoside Analogue-Resistant Orolabial Herpes Simplex Virus 2 in a Person Living with HIV
Andrew Purssell, Kennedy Leung, Pierre Giguère, Jonathan B Angel
Volume 9 Issue 2, June 2024, pp. 108-112
Evaluation Of The Clinical Drug-Drug Interaction Potential Of Pritelivir On Transporters And Cyp450 Enzymes Using A Cocktail Approach
Michiel de Vries, Susanne Bonsmann, Jörg Pausch, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Dirk Kropeit
Clin Pharmacol Drug Dev. 2024 May 16. doi/10.1002/cpdd.1408
Mass Balance and Metabolite Profile After Single and Multiple Oral Doses of Pritelivir in Healthy Subjects
Susanne Bonsmann, David McCormick, Jörg Pausch, Michiel de Vries, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Dirk Kropeit
Clin Pharmacol Drug Dev. 2024 Apr;13(4):389-403. doi: 10.1002/cpdd.1358. Epub 2024 Jan 8.
A Multi-Center Assessment of The Outcomes and Toxicities of Foscarnet for Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex in Immunocompromised Patients
Sarah P Hammond, Manickam Rangaraju, Melanie Sumner, Burkhard Timmler, Pranatharthi Chandrasekar, Robin K Avery
Open Forum Infect Dis. 2024 Feb 5;11(3):ofae046. doi: 10.1093/ofid/ofae046. eCollection 2024 Mar.
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Domenico Russo, Michael Schmitt, Sylvain Pilorge, Matthias Stelljes, Toshiro Kawakita, Valerie L Teal, Barbara Haber, Charlene Bopp, Sanjeet S Dadwal, Cyrus Badshah
Lancet Haematol. 2024 Feb;11(2):e127-e135. doi: 10.1016/S2352-3026(23)00344-7. Epub 2023 Dec 21.
Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation
Li, Wen-Wena,Zhang, Yong-Meia, Shen, Meng-Zhua, Mo, Xiao-Dong
Blood Science 6(1):p e00178, January 2024. | DOI: 10.1097/BS9.0000000000000178
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial
Ajit P Limaye, Klemens Budde, Atul Humar, Flavio Vincenti , Dirk R J Kuypers, Robert P Carroll, Nicole Stauffer, Yoshihiko Murata 9, Julie M Strizki 9, Valerie L Teal, Christopher L Gilbert, Barbara A Haber
JAMA. 2023 Jul 3;330(1):33-42. doi: 10.1001/jama.2023.9106.
Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients
Davide Bosetti, Chiara Bernardi, Marie Maulini, Federica Giannotti, Anne-Claire Mamez, Stavroula Masouridi-Levrat, Yves Chalandon, Dionysios Neofytos
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0173222. doi: 10.1128/aac.01732-22. Epub 2023 Mar 27.
First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy Subjects
Kropeit D., Bonsmann S., von Richter O., McCormick D., Pausch J., Sumner M., Birkmann A., Zimmermann H., Rübsamen-Schaeff H.
Clin Pharmacol Drug Dev. 2023 Mar 1. doi: 10.1002/cpdd.1241